HF
PHAT icon

HRT Financial’s Phathom Pharmaceuticals PHAT Stock Holding History

HRT Financial’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,010
Closed -$448K – 4512
2025
Q4 		$448K Buy
27,010
+4,489
+20% +$64.1K ﹤0.01% 2165
2025
Q3 		$265K Buy
+22,521
New +$232K ﹤0.01% 2253
2025
Q2 		– Sell
-33,297
Closed -$208K – 3329
2025
Q1 		$208K Buy
+33,297
New +$202K ﹤0.01% 2005
2022
Q4 		– Sell
-52,801
Closed -$585K – 2977
2022
Q3 		$585K Buy
+52,801
New +$503K 0.01% 1332
2020
Q2 		– Sell
-10,980
Closed -$283K – 1713
2020
Q1 		$283K Buy
+10,980
New +$367K 0.02% 509

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

HRT Financial's PHAT Position: Q1 2026 in Review

HRT Financial sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 27,010 shares — an estimated $448K sold.

HRT Financial first reported a position in PHAT in Q1 2020 and held it in 5 quarters. The position peaked at $585K in Q3 2022. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • HRT Financial reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 27,010 Phathom Pharmaceuticals shares in Q1 2026, an estimated $448K.
  • HRT Financial first reported a position in Phathom Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • HRT Financial's Phathom Pharmaceuticals position peaked at $585K in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.